Full-Time

Finance Planning & Analysis Manager

Posted on 5/12/2026

Deadline 5/19/26
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Global biopharma researching, developing, delivering medicines

No salary listed

Hyderabad, Telangana, India

Hybrid

Hybrid role; ~50% on-site in Hyderabad; travel up to 10%.

Category
Accounting (2)
,
Required Skills
Oracle Hyperion
Forecasting
SAP Products
Financial analysis
Data Governance
Requirements
  • Bachelor's Degree in Business, Finance, Engineering or a related field required; Masters Degree preferred
  • Minimum of 5-7 years of experience
  • Strong knowledge of management reporting processes, including implementation and process improvement experience
  • Proficiency in analyzing process performance and systems capabilities to define and oversee process improvement projects through design and oversight to execution and delivery of expected business results
  • Experience working for a multinational organization and working with colleagues internationally, especially in a highly collaborative manner and culture
  • Experience with global teams and/or centers of excellence
  • Proficiency in English language
  • Ability and willingness to travel internationally as needed
  • Familiarity with SAP, SAP BI, and Hyperion related software applications
Responsibilities
  • FP&A activities: Performs FP&A Management Reporting activities for regional and senior management consumption
  • FP&A activities: Builds budget, forecasting and projections for the markets
  • FP&A activities: Provides effective analyses to clearly highlight key trends / variances and rationale
  • FP&A activities: Prepares presentations for budget & projection reviews; updates forecast templates as needed
  • FP&A activities: Prepares analysis of monthly actual variances vs. budget / projection in alignment with standard framework and templates
  • FP&A activities: Executes special projects, ad-hoc analysis to ensure highly effective outcomes
  • Process standardization and improvement: Support Director FP&A Operations, who is responsible for FP&A Operations processes and activities
  • Process standardization and improvement: Support the development and execution of a global strategy for policies, processes, and technologies
  • Process standardization and improvement: Define and establishing consistent end to end process, KPIs and targets and intervene accordingly to drive results improvement
  • Process standardization and improvement: Collaborate with data owners / stewards to align on process and data issues
  • Process standardization and improvement: Propose management reporting forecasting improvement projects with a focus on delivering key business outcomes
  • Process standardization and improvement: Develop the business case for process improvement decisions, and tracks actuals against the plan to validate execution and improve future plans
  • Process standardization and improvement: Participate in process governance
  • Process standardization and improvement: Identify, design and incorporate industry leading practices into standard operations within the Hyderabad Hub necessary to identify, and raise / resolve issues involving tradeoffs, especially around cost, quality, and customer service
  • Process standardization and improvement: Maintain to a culture of continuous improvement at all levels of the organization and foster a business-oriented culture; continuously monitor the needs of the business
  • Process standardization and improvement: Solicit feedback from internal customers, both operationally and regionally to determine the best response to continually improve process performance and year-over-year cost reductions
  • Process standardization and improvement: Ensure and continually validate operating procedures are established and documented to support execution, and are maintained to align with process changes
  • Process standardization and improvement: Ensure management reporting services are provided to the markets at competitive costs and leading service levels
  • Relationship management and teaming: Collaborate with Corporate FP&A to ensure adherence to corporate policies and procedures, and adjust processes to reflect changes required
  • Relationship management and teaming: Build and maintain relationships at all levels throughout the organization, specifically with Hyderabad Hub and global Finance leadership
  • Relationship management and teaming: Build an external network to ensure regular exposure to new and best practices, technologies, and process governance standards
  • Relationship management and teaming: Hold self and others to timelines, quality, and accuracy
  • Risk management: Anticipate needs, assess and manage business risk taking; escalate issues that may impact management reporting process globally; manage through times of crisis and ambiguity
Desired Qualifications
  • Masters Degree preferred
  • Proven professional with ability to influence the highest levels of the organization
  • Skilled in building strong external and internal strategic relationships and coalitions
  • Highly competent in influencing without authority through knowledge, skills, and relationships
  • Skilled in managing a portfolio of business issues that cross short- and long-term strategic objectives
  • Strong communication skills / able to persuade / influence others at all organization levels
  • Familiarity with SAP, SAP BI, and Hyperion related software applications

Bristol Myers Squibb develops and sells medicines for serious diseases, focusing on cancer, immune system disorders, and cardiovascular conditions. Its work starts with research and development to create new therapies, which are then approved by regulators before being used by doctors and patients; the company also offers generic versions and supports biosimilars to expand access. BMS differentiates itself with a broad portfolio of innovative medicines alongside affordable options and a strong emphasis on ESG and regulatory engagement. The goal is to improve patient health by delivering effective, affordable medicines and advancing sustainable healthcare globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth Portfolio averages 16% YoY growth over two years per Q1 2026 results.
  • Eliquis on Cost Plus Drugs at $345/30-day expands access from April 27.
  • FoundationOne CDx expansion detects MTAP deletion for targeted oncology therapy.

What critics are saying

  • Eliquis generics from Apotex erode $14.4B sales post-2026 patent expiry.
  • Revlimid sales plunge drives 5.1% revenue drop in next 12 months.
  • FDA revoked Krazati approval May 5, 2026, after failed NSCLC PFS trial.

What makes Bristol Myers Squibb unique

  • Mezigdomide plus carfilzomib beats Kd in SUCCESSOR-2 Phase 3 PFS for RRMM.
  • Sotyktu gains EU approval May 2026 for psoriatic arthritis post-POETYK trials.
  • Cobenfy switch study shows 8-week PANSS stability from atypicals in schizophrenia.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Bristol Myers Squibb who can refer or advise you

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

360Dx
Apr 21st, 2026
In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion.

In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion. NEW YORK - Foundation Medicine said Tuesday that it has expanded an ongoing collaboration with Bristol Myers Squibb to develop FoundationOne CDx as a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy. Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month

Yahoo Finance
Apr 13th, 2026
Bristol Myers Squibb: 4.2% dividend yield and stable revenue at bargain valuation

Bristol Myers Squibb presents an attractive value investment in the pharmaceutical sector, with a forward price-to-earnings ratio of 9.5, significantly lower than competitors Johnson & Johnson (21) and Merck (24). The company offers a 4.2% dividend yield and has increased payouts for 17 consecutive years. Bristol reported $48.2 billion in revenue for 2025, with 2026 guidance between $46 billion and $47.5 billion, demonstrating consistency despite modest decline. However, the favourable valuation reflects investor concerns about slowing legacy portfolio revenue, which fell from $25.7 billion in 2024 to $21.8 billion in 2025. Key challenges include an upcoming patent cliff for Eliquis, its blood thinner generating $14.4 billion in 2025 sales, and the $1.5 billion acquisition of Orbital Therapeutics whilst carrying over $47 billion in debt.

Yahoo Finance
Apr 10th, 2026
Bristol Myers' Cobenfy hits $155M in first year, outpacing rival schizophrenia treatments

Bristol Myers Squibb's schizophrenia drug Cobenfy generated $155 million in sales during 2025, outpacing comparable treatments in its first year following FDA approval in September 2024. The medication represents the first new pharmacological approach to treating schizophrenia in decades. Recent phase II data presented at the Schizophrenia International Research Society Annual Congress showed adults with schizophrenia remained stable after switching to Cobenfy monotherapy over eight weeks, with low discontinuation rates and no dropouts due to lack of efficacy. Bristol Myers is pursuing label expansions across multiple indications, with ongoing phase III studies in Alzheimer's disease psychosis, agitation, cognitive impairment, bipolar I disorder and paediatric irritability associated with autism. The company expects Cobenfy to become a significant growth driver as legacy drugs face generic competition.

Buzzword News
Mar 30th, 2026
Bristol Myers Squibb adding 3 medications on TrumpRx.

Bristol Myers Squibb adding 3 medications on TrumpRx. Mar 30, 2026 - 14:01 EXCLUSIVE: Bristol Myers Squibb is launching three medications on TrumpRx.gov on Monday, FOX Business has learned. The three prescription drugs will each be offered at deep discounts that range from 40% to 90% off the retail price. The Princeton, New Jersey-based company's drug Sotyktu retails for $7,135.55 and will be offered through TrumpRx.gov for $743. That represents a 90% discount off what patients have been paying. Sotyktu treats adults with moderate-to-severe plaque psoriasis. Zeposia, which treats relapsing forms of multiple sclerosis, will be added at a discount of between 88% and 90%. The weekly injection to treat moderate-to-severe rheumatoid arthritis, Orencia SC, will be reduced by 40% from the retail price. A White House official said this is the latest big pharma company to offer reduced prices after the tariff pressure from President Donald Trump. The talks with pharmaceutical companies continue to be successful, with more medications added to the government website. Bristol Myers' additions come weeks after FOX Business reported that Amgen and GSK were added to the list of prescription drug manufacturers offering discounts on the government website. Amgen offers medications on the website that cut 80% off the retail price. Amjevita has an original price of $1,484, but will be available on TrumpRx.gov for $299. The medication treats rheumatoid arthritis, psoriasis and ulcerative colitis. Amgen also lists Aimovig and Repatha for discounts of 62%. GSK discounts Incruse at 55% off the retail price. The drug treats COPD and will be listed at $159.20. GSK lists Arnuity, Relenza and Anoro at discounts ranging from 10% to 51%. The White House is pushing ahead with announcements to TrumpRx.gov as Americans look for ways to cut medical costs. Under the Biden administration, Bureau of Labor Statistics data shows, prescription drug costs increased 10.4% from January 2021 to January 2025. Under the Trump administration, prescription drug prices increased 0.2% from January 2025 through the latest data from February 2026.

Insider Monkey
Mar 30th, 2026
Bristol-Myers Squibb gets FDA approval for Hodgkin's Lymphoma treatment.

Bristol-Myers Squibb gets FDA approval for Hodgkin's Lymphoma treatment. Published on March 30, 2026 at 2:07 am by sultan khalid in news. Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Large Cap Stocks with Highest Dividends. Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company (NYSE:BMY) announced on March 20 that the U.S. Food and Drug Administration had approved the company's combination treatment for adults and adolescents aged 12 and older with previously untreated stage III or IV classical Hodgkin's lymphoma. The antitumor therapy, called Opdivo, had previously received the green light to treat various advanced or metastatic cancers, including melanoma, non-small cell lung cancer, and kidney cancer. The regulatory authority's decision is based on a late-stage study of 994 patients, which demonstrated that the treatment significantly improved progression-free survival compared with brentuximab vedotin. Hodgkin's lymphoma, also known as Hodgkin's disease, is the most common form of cancer in patients aged 15 to 19. It starts in white blood cells, which are part of the body's immune system, a cancer that starts in white blood cells. Monica Shaw, MD, Senior Vice President of Oncology Commercialization at Bristol-Myers Squibb Company (NYSE:BMY), stated: "These approvals represent a defining moment for people living with classical Hodgkin Lymphoma. In the U.S., we are particularly proud that Opdivo in combination with AVD now stands as an immunotherapy combination available for adults and pediatric patients, ages 12 and older, with previously untreated advanced disease. Concurrently, in the EU, Opdivo in combination with brentuximab vedotin has also achieved a milestone as the first immunotherapy combination for certain relapsed or refractory patients. These milestones reflect our continued commitment to advancing science that meaningfully improves the lives of patients and families worldwide." While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.